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Abstract: Transcription is regulated by two major mechanisms. On the one hand, changes in DNA sequence are responsi-
ble for genetic gene regulation. On the other hand, chromatin structure regulates gene activity at the epigenetic level. 
Given the fundamental participation of these mechanisms in transcriptional regulation of virtually any gene, they are 
likely to co-regulate a significant proportion of the genome. The simple concept behind this idea is that a mutation may 
have a significant impact on local chromatin structure by modifying DNA methylation patterns or histone type recruit-
ment. Yet, the relevance of these interactions is poorly understood. Elucidating how genetic and epigenetic mechanisms 
co-participate in regulating transcription may assist in some of the unresolved cases of genetic variant-phenotype associa-
tion. One example is loci that have biologically predictable functions but genotypes that fail to correlate with phenotype, 
particularly disease outcome. Conversely, a crosstalk between genetics and epigenetics may provide a mechanistic expla-
nation for cases in which a convincing association between phenotype and a genetic variant has been established, but the 
latter does not lie in a promoter or protein coding sequence. Here, we review recently published data in the field and dis-
cuss their implications for genetic variant-phenotype association studies. 
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CHALLENGES IN DETERMINING GENETIC VARI-
ANT-PHENOTYPE ASSOCIATIONS 
Sequence Variants Located Outside Promoter and Pro-
tein Coding Regions 
  Genetic variants (GVs) are distributed across the genome 
in both coding and non-coding sequences. In fact, selective 
pressure tends to decrease the frequency of GVs within ex-
ons, in comparison with promoters and introns. This phe-
nomenon has been clearly illustrated by a study addressing 
the genome-wide distribution of single nucleotide polymor-
phisms (SNPs) [1]. The authors found average SNP densities 
(i.e. number of SNPs per 10 kb) of 8.33, 8.44, and 8.09 in the 
whole genome, in intergenic and genic regions, respectively. 
A closer look at genic regions revealed SNP densities of 
8.21, 5.28, and 7.51 in intronic, exonic and 5’ or 3’ untrans-
lated regions, respectively. The implication of these observa-
tions is that a vast number of non-coding sequence GVs is 
likely to be identified by genetic screenings as potential phe-
notype modifiers. This conclusion has been supported by a 
recent meta-analysis of genome-wide genetic studies show-
ing that a large proportion (39%) of SNPs associated with 22 
common human diseases are intergenic [2]. Yet, traditional 
views of gene function and regulation tend to filter out non-
coding sequence GVs as functionally neutral, while stressing 
the importance of promoter or exon GVs in transcription 
factor binding or reading frame alteration and consequent   
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phenotypic modification. A further complication is that non-
coding GVs often lie within genes that represent excellent 
candidate phenotype modifiers based on their function. The 
following are representative examples of many found in the 
literature. One such example is the transcription factor 7-like 
2 (TCF7L2) gene and the role of SNPs present in that gene in 
type 2 diabetes. TCF7L2 encodes a high mobility group box-
containing transcription factor that has been implicated in 
blood glucose homeostasis [3]. Genetic variants of this gene 
are associated with increased risk of type 2 diabetes, and 
extensive genome-wide association studies have identified 
TCF7L2 as a type 2 diabetes susceptibility gene. Noticeably, 
TCF7L2 SNPs have been demonstrated to have by far the 
biggest effect on the risk of developing type 2 diabetes, in 
comparison with all SNPs studied to date. In particular, 
SNPs located in TCF7L2 intron 4 and 5 – i.e. rs12255372 
and rs7903146 – have shown robust associations with type 2 
diabetes in a Danish and US cohort [4]. These observations 
are supported by independent studies in other ethnic groups 
[5]. How these SNPs located in introns affects the expression 
of TCF7L2, and therefore the risk of type 2 diabetes, remain 
largely unknown. A second relevant example is rs9939609, a 
SNP located in the fat mass and obesity associated (FTO) 
gene. FTO has attracted a huge interest, as it was identified 
by genome-wide studies as a susceptibility gene for type 2 
diabetes. Furthermore, diabetes risk-associated FTO alleles 
were also strongly associated with increased body mass in-
dex (BMI), a measure of obesity, strongly suggesting that the 
association of FTO GVs with type 2 diabetes risk is secon-
dary to effects on BMI. The relevant GV is in this case a 
cluster of 10 SNPs in the first intron of FTO that are associ-
ated with both traits [6]. rs9939609 was used in all further 360    Current Genomics, 2010, Vol. 11, No. 5  Zaina et al. 
studies because among the cluster of most highly associated 
SNPs it had the highest genotyping success rate (see for ex-
ample the recent study by Gu et al. [7]). Another useful ex-
ample is the association between receptor estrogen alpha 
(ESR1) gene GVs and endometrial cancer. ESR1 is the main 
estrogen receptor expressed in the endometrium and has 
been proposed to play a pivotal role in determining endo-
metroid endometrial carcinoma risk, the most common his-
tological subtype among endometrial malignancies [8]. 
Among  ESR1 SNPs analyzed, rs9340799A/G and 
rs2234693T/C were associated with a significant reduction 
in disease risk. rs9340799GG genotype associated with 
nearly 50% decreased risk for endometrial cancer compared 
to AA genotype (OR 0.53; CI 0.37-0.77), while the effect of 
rs2234693C/C genotype was less pronounced (OR 0.65 CI 
0.48-0.89) [9]. These SNPs are found in a 46 bp region of 
ESR1 intron 1. 
Genetic Variants that Lie in Biologically Relevant Genes 
but are Poorly Associated with Phenotype 
  Another type of challenge faced at times by genetic asso-
ciation studies is the dilemma of biologically strong candi-
date genes containing GVs that perform very poorly in geno-
type/phenotype association tests. A further layer of complex-
ity is that the significance of association tests in some cases 
varies significantly between studies conducted in different 
countries and ethnic groups. Again, examples of GVs with 
these characteristics abound in the literature and involve 
genes for which a pivotal role in various important diseases 
has been proposed based on functional data. The Q223R 
polymorphism in the leptin receptor gene (LEPR) is one ex-
ample. LEPR mediates the main biological effects of leptin, 
i.e. the imposition of a negative feedback signal in regulating 
body-weight through reduction of food intake and stimula-
tion of energy expenditure [10]. Leptin being a fundamental 
factor in body weight regulation, the identification of GVs 
modulating its pathophysiological effects is of potentially 
enormous importance. The LEPR GV in question consists of 
an A to G transition at position 668 in exon 6, resulting in a 
substitution of an arginine for glutamine located in the ex-
tracellular domain of the encoded receptor protein, thus mak-
ing this GV a seemingly straightforward predictor of bio-
logical function [11]. The results of genetic association stud-
ies for LEPR Q223R polymorphism vary dramatically across 
different studies. On the one hand, the observed allelic fre-
quency differs among countries and ethnic groups. In par-
ticular, the frequency of the 223R allele for Asians was sig-
nificantly higher than for other ethnicities [12]. On the other 
hand, significant effects of this GV on obesity were reported 
in two early meta-analysis [12, 13], and was confirmed by 
more recent studies [14-18]. However, its association with 
obesity is generally regarded as controversial, given that 
reports showing only weak or no association at all have been 
published [19, 20]. 
  A second relevant example is the S810L point mutation 
of the mineralocorticoid receptor (MR) gene. This is a TCA 
to TTA missense mutation at nucleotide 810 in exon 6 that 
results in substitution of serine with leucine in the hormone-
binding domain of the encoded receptor. This change leads 
to an increased, ligand-independent baseline activity of the 
receptor and consequent hypertension [21]. In addition, the 
mutation increases the affinity of MR for progesterone and 
confers agonist activity to other steroids that are normally 
MR antagonists. The mutation showed a precise (100%) as-
sociation with repeated severe pregnancy-induced hyperten-
sion in a US population sample [22]. This very convincing 
result contrasts with the conclusions of a recent work by our 
group addressing the mutation association with gestational 
hypertension. The latter study found similar genotype fre-
quencies among hypertensive and normotensive women 
(12% vs 9.4%) [23], thus suggesting that population-specific 
differences play a significant role in this case. A further 
complication affecting the study of the MR S810L mutation 
is its extreme rarity or absence in selected populations, as 
demonstrated by studies including women affected by preg-
nancy-induced hypertension, preeclampsia and essential hy-
pertension [24-26]. 
  Another factor implicated in metabolic diseases is adi-
ponectin (ADIPOQ), representing the most abundant adipo-
cyte-derived protein. ADIPOQ exhibits antiatherogenic and 
antiinflammatory properties, in addition to induce antidia-
betic effects due to insulin sensitizer activity [27, 28]. In 
accordance with its biological activities and perhaps in con-
trast with the fact that ADIPOQ is produced mainly in the 
adipose tissue [29], obese subjects have significantly lower 
plasma ADIPOQ concentration than non-obese subjects [30]. 
Adiponectin levels have a strong genetic component, with 
heritability estimated between 30 and 50% [31]. Therefore 
not surprisingly, ADIPOQ has been identified as an impor-
tant susceptibility locus for metabolic syndrome, type 2 dia-
betes and cardiovascular disease [32, 33]. In particular, the 
association of 5´ region SNPs rs17300539 (-11391G>A) and 
rs266729 (-11377C>G), rs2241766 (45T>G) in exon 2 and 
rs1501299 (276G>T) in intron 2 with adiponectin level, in-
sulin resistance and obesity has been extensively studied, but 
often with inconsistent results. For instance, the ADIPOQ 
45G allele was associated with higher risk of obesity and 
insulin resistance in a German population [34] but protective 
among Taiwanese [35, 36]. Lack of consistency has been 
observed for ADIPOQ 276G>T polymorphism in which the 
increased risk of obesity and insulin resistance was associ-
ated with 276T allele among Italians [37] but with 276G 
allele among Greek women [38]. The SNPs -11391G>A and 
-11377C>G had shown strong association with adiponectin 
levels [39-41]. The 45T/G and 276G/T SNPs also have been 
associated with serum adiponectin [39, 41, 42]. 
  As expected, the inconsistent associations involving the 
GVs presented above have been the objective of much 
speculation. Although a number of factors such as sample 
size could be responsible, it is possible that yet poorly char-
acterized genetic regulatory mechanisms, differential envi-
ronmental or diet exposure play an additional, perhaps 
equally important role. In the following paragraphs, we will 
discuss how epigenetics provides a conceptual framework 
that takes into account allele-environment and allele-diet 
interactions and may improve our understanding of complex 
genotype-phenotype associations. 
EPIGENETICS, CHROMATIN 
  Although various definitions of epigenetics have been 
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as the study of mechanisms of gene regulation that are de-
pendent on chromatin architecture. This definition is distinct 
from the one of functional genetics, which singles out DNA 
sequence variants as determinants of gene expression. 
Chromatin is a high-order structure that in addition to serve 
the purpose of compacting the ~2 m.-long DNA chain con-
tained in a typical high eukaryote cell nucleus, regulates 
gene transcription. Nuclear chromatin is a nucleoprotein 
complex in which DNA is wrapped around octamers of his-
tone proteins called “core histones”, which include two cop-
ies of each histone type 2A, 2B, 3 and 4. The fundamental 
repetitive unit of chromatin is called nucleosome, defined as 
one core histone octamer and the DNA wrapped around it. 
Transcription of a given gene is affected by the architecture 
of chromatin in which the gene is embedded. Generally 
speaking, chromatin architecture can be classified into two 
main types, a compact one in which genes are silent (non-
permissive chromatin), and a more relaxed one, permissive 
of transcription, in which gene promoters are accessible to 
the transcription machinery [44]. 
  A number of molecular modifications of DNA and his-
tones constitute epigenetic marks that are specifically associ-
ated with permissive or non-permissive chromatin. DNA 
methylation and histone posttranslational modifications are 
the most studied epigenetic marks. DNA methylation in 
mammals occurs mostly at position 5 of cytosine residues in 
a CpG dinucleotide context to yield 5-methyldeoxycytidine 
(5mdC). The various known histone modifications include 
acetylation, methylation, phosphorylation and sumoylation. 
A specific combination of epigenetic modifications deter-
mines or reflects the transcriptional status of a given DNA 
regions. For example, DNA hypomethylation, histone hy-
peracetylation and hypomethylation of Lys 20 of histone 4 
are modifications generally associated with active DNA re-
gions, whereas the reciprocal modifications are present in 
inactive regions of the genome [44]. In addition, regulatory 
element-specific epigenetic marks have been uncovered. For 
example, promoters and enhancers display characteristic 
nucleosome-free sites but differ in the degree of histone 3 
Lys 4 methylation [45]. Although several exceptions proba-
bly exist, epigenetic marks occupy a region of variable size 
rather than being punctual and when de novo imposed often 
spread to adjacent sequences, as early work on promoter 
DNA methylation demonstrated [46].  
  All epigenetic modifications present in a given cell nu-
cleus at a given point in time are collectively referred to as 
epigenome. The epigenome is at least in part a plastic entity, 
i.e. cell growth and differentiation are often associated with 
changes in DNA methylation status and collection of histone 
modifications at specific loci. One extreme example of this 
phenomenon is the widespread erasure and re-establishment 
of DNA methylation patterns during mammalian embryo 
development, clearly illustrating the reversible character of 
epigenetic changes [47]. Epigenetic patterns differ between 
different cell types, implying that different epigenomes coex-
ist in a genetically uniform organism [48]. Indeed, plasticity 
is a unique characteristic of the epigenome, which can be 
described as a fluctuating entity during development and cell 
differentiation, distinct from dynamics that shape the ge-
nome,  i.e. generally irreversible mutations. Despite being 
plastic, epigenetic marks are maintained upon cell division, 
indicating that a degree of stability is another fundamental 
property of epigenetic marks at least in a homogeneous, not 
differentiating cell population. 
  Deviations from the physiological epigenome are be-
lieved to play a significant role in numerous diseases such as 
cancer, mental disorders and atherosclerosis [49, 50]. In the 
case of cancer, a frequently observed epigenetic change is 
global loss of 5mdC (DNA hypomethylation) and concomi-
tant hypermethylation of a subset of CpG-rich regions called 
CpG islands, typically located in promoter regions. Given 
the occurrence of epigenetic alterations in disease, much 
effort is directed towards understanding what factors regu-
late the equilibrium between stability and dynamic changes 
of the epigenome, and their mechanisms of action. It is clear 
that factors exogenous to the organism play a role in these 
changes. Broadly speaking, these exogenous forces include 
at least diet and environmental factors. Seminal observations 
in animal models and in humans provide proof of principle 
that diet and environment act indeed as epigenome modifiers 
[51, 52]. In particular, specific environmental risk factors for 
cardiovascular disease have been recently linked to hy-
pomethylation of a substantial part of the genome in humans 
[52]. Based on these observations, it is widely believed that 
changes in the population’s exposure to diet-related and life 
style-related factors induce epigenetic changes that in turn 
contribute to the recent epidemics of metabolic diseases such 
as obesity, diabetes, metabolic syndrome and vascular com-
plications [53]. 
GENETIC VARIANTS CAN AFFECT EPIGENETIC 
MARKS 
  The concepts presented in the last paragraph offer hints 
to understand on the one hand how non-promoter and non-
coding GVs can impact on transcription, and on the other 
hand why genetic associations are in some cases unexpect-
edly poor or inconsistent in different studies. In both in-
stances, it is possible that GVs are associated with changes 
in DNA methylation patterns or histone marks, which in turn 
can provoke rearrangements of chromatin architecture that 
may have long-range transcriptional effects. For example, an 
intronic SNP-imposed DNA methylation state, if affecting 
the methylation state of a nearby promoter, would in princi-
ple exert the same effect as a transcription factor binding 
site-disrupting mutation. In the next paragraphs, we provide 
examples of evidence and proposed mechanisms that support 
the existence of cross-talks between genetic background and 
epigenetic marks. 
Sequence-Specific Regulation of DNA Methylation 
  A number of observations indicate that GVs have an im-
pact on DNA methylation. One well-known, straightforward 
mechanism is the depletion of methylable sites, i.e. CpG 
dinucleotides. Work in the late eighties has demonstrated 
that G/A (C/T in the opposite strand) transitions are the most 
common point mutations in the human v-Ki-ras2 Kirsten rat 
sarcoma viral oncogene homolog (KRAS) gene [54]. Ge-
nome-wide scale studies subsequently confirmed these early 
observations [55]. In particular, the latter study generalized 
previous observations that C/T transition is a major force 
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phenomenon that is at least in part driven by natural decay of 
5mdC. Thus, it can be proposed that GVs can epigenetically 
regulate transcription by disrupting binding sites for regula-
tory proteins that recognize 5mdC. Disrupting events can 
include CpG destruction, as 5mdC-binding factors can bind 
to sequences containing a single 5mdCpG dinucleotide, or 
loss of A/T runs close to methylated sites needed by some of 
those factors for DNA binding [56, 57]. At least two studies 
demonstrate that punctual loss or gain of DNA methylation 
secondary to destruction of a single CpG nucleotide by a T/C 
or G/A SNP, greatly affects promoter activity of matrix met-
alloproteinase 1 (MMP1) and potassium-chloride co-
transporter 3 (SLC12A6) genes [58, 59]. Noticeably, those 
SNPs are medically relevant as have been linked with risk of 
preterm premature rupture of membranes and psychiatric 
disorders, respectively. Furthermore, if a GV results in punc-
tual depletion of a methylable site and this has spreading 
effects on adjacent sequences, one would expect to observe 
an association between DNA methylation state and proximal 
DNA sequence. This prediction has been demonstrated to 
hold true by a seminal work showing that specific SNP geno-
types associate with specific DNA methylation patterns and 
possibly act as modifiers of DNA methylation in cis [60]. By 
interrogating SNP arrays with methylation-filtered genomic 
DNA obtained from a number of human tissues, the authors 
showed that allele-specific DNA methylation (ASM) was 
specifically associated with adjacent SNP genotype in a 
number of loci. Importantly, SNP genotype-specific DNA 
methylation states were strongly correlated with allele-
specific expression. A recent study expanded these observa-
tions by addressing the impact of SNPs located at CpG 
dinucleotides on ASM [61]. The work stemmed from the 
observation that one characteristic epigenetic feature ob-
served during nuclear reprogramming is the presence of in-
termediate CpG methylation states – i.e. ~50% - at selected 
loci, even in monoclonal cell lines. Since this intermediate 
methylation state could not be explained by imprinting or X 
chromosome inactivation, the authors turned their attention 
to ASM. The study was conducted in various human pluripo-
tent cell lines and constitutes the largest human ASM survey 
to date. The results showed methylation states that specifi-
cally associated with one allele of a SNP. Strikingly, a major 
fraction (38-88% depending on the cell line considered) of 
ASM is determined by CpG dinucleotide-containing SNPs, 
thus supporting the idea that disruption of CpG sites is a ma-
jor determinant of differential methylation. This observation 
is likely to have important implications for genome biology, 
as databases list >200,000 CpG nucleotide-associated SNPs 
in the human genome (discussed in [61]). The obvious ques-
tion is what factors are involved in SNP-operated ASM cis-
regulation. Results of genomic approaches offer a complex 
picture, as they suggest that a given CpG dinucleotide-
containing SNP impacts DNA methylation if it is included in 
a region normally targeted by epigenetic regulators [61]. 
Clearly, these exciting results have to be complemented by 
mechanistic studies, above all to clarify the role of sequences 
adjacent to a given SNP as opposed to the effects of the SNP 
per se. A schematic view of phenomena described in this 
paragraph is presented in Fig. (1A). 
  In addition to a single nucleotide GV, a deletion or inser-
tion can impact epigenetic marks in neighbouring sequences. 
This phenomenon has been documented in a variety of mod-
els, as in the classic example the A
vy allele of the mouse 
Agouti gene. The A
vy allele contains an upstream inserted 
intra-cisternal A particle (IAP) retrotransposon, which de-
termines the erasure of repressive DNA methylation marks 
and ectopic Agouti expression [62]. A recent report illus-
trates the occurrence of a similar mechanism in a gene that is 
relevant for human health [63]. The authors addressed 
mechanisms of the DNA mismatch repair MSH2 gene silenc-
ing in cancer-prone Lynch syndrome patients. The intriguing 
observation was that MSH2 promoter hypermethylation and 
silencing was associated with active transcription of a mu-
tated allele of the epithelial cell adhesion molecule gene 
(EPCAM or TACSTD1), located upstream to MSH2. The 
mutated EPCAM allele bears a 3` end deletion encompassing 
polyadenylation signals, resulting in transcript extension into 
the MSH2 gene. The authors propose that unscheduled tran-
script extension-induced repressive epigenetic marks may be 
a common source of gene silencing (Fig. 1B). This provok-
ing idea is yet to be confirmed, but the notion that unsched-
uled RNA polymerase transit through a promoter imposes 
DNA methylation is plausible in the light of evidence that 
intragenic DNA methylation is a landmark of transcribed 
genes (discussed below in paragraph “Genetic variants, epi-
genetic marks and splicing”). 
GVs and Histone Marks 
  In addition to DNA methylation, histone marks can be 
modified by SNPs, as a recent study clearly illustrates [64]. 
The authors analysed a particularly relevant SNP 
(rs6983267) in the context of this review, located intergeni-
cally and notably distal (335 kb) from the nearest gene, i.e. 
c-MYC. The interest in this particular SNP originated from 
previous genetic evidence that it is significantly linked to 
risk for a variety of cancer types, and from the fact that 
mechanisms by which this SNP impacts c-MYC transcription 
remained elusive [65]. Results revealed that rs6983267 is 
part of a chromatin loop that allows large-distance interac-
tion with the c-MYC promoter. Interestingly, the chromatin 
loop appears to be a constitutive feature of that region, as its 
presence is not associated to rs6983267 genotype. Rather, 
the rs6983267 G allele displays an enhancer-like histone 
mark that accounts for allele-specific c-MYC promoter acti-
vation [64]. These findings are important, as they show that 
two chromatin architecture-related mechanisms, i.e. a change 
in histone mark and a facilitating chromatin loop, concur to 
allow long-range transcriptional control by an intergenic 
SNP. Therefore, the study provides a model mechanism that 
can be easily tested for other intergenic or non-coding SNPs 
(Fig. 1C). 
Genetic Variants, Epigenetic Marks and Splicing 
  If the transcriptional impact of GVs that affect epigenetic 
marks at promoter or enhancers is relatively straightforward 
to envision, the effects of gene body – i.e. introns and exons 
- chromatin modifications are only beginning to be under-
stood. The first comprehensive study addressing this issue 
was conducted in the plant A. thaliana and revealed that 
gene body methylation is a feature associated with interme-
diately expressed genes, rather than being a silencing mark 
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methylation in humans [67]. The authors mapped genome-
wide DNA methylation patterns at progressive differentia-
tion stages between human embryonic stem cells and fully 
differentiated fibroblasts. A consistent feature of transcribed 
genes was promoter hypomethylation as expected and, in 
addition, high gene body methylation. Although these marks 
correlated with expression, transcriptional effects of gene 
body methylation may be subtle, as exons were more methy-
lated than introns and a sudden transition in DNA methyla-
tion levels marked exon-intron boundaries. The latter obser-
vation is important, as it suggests that gene body DNA 
methylation could be involved in differential splicing, possi-
bly independently of absolute transcript levels. In addition to 
DNA methylation, histone marks are believed to be involved 
in splicing, as shown by a study addressing the mechanisms 
for neural cell adhesion molecule 1 (NCAM1) gene exon 18 
exclusion upon depolarization of neuronal cells [68]. In this 
controlled system, depolarization resulted in the accumula-
tion of hyperacetylated histone 3 Lys 9 at the differentially 
spliced portion of the gene. Interestingly, a slow RNA po-
lymerase II mutant favoured exon 18 inclusion, suggesting 
that histone marks affect splicing by dictating the elongation 
rate. A recent review extensively discusses this crucial topic 
[69].  
  The implication of these findings is that exploring the 
interplay between epigenetic marks, splicing and protein 
function may help to interpret cases of inconclusive genetic 
associations. To mention just a few examples among the 
ones discussed in the first section of this review, gene body 
GVs in MR and LEPR may result in alternative splicing as a 
result of epigenetic marks that may be under the dual control 
of GV genotype and environmental factors. Notably, LEPR 
is present in 3 splice variants (NM_002303.3, 
NM_001003679.1 and NM_001003680.1, respectively), 
offering the testable hypothesis that gene body polymor-
phisms affect DNA methylation states that spread to the al-
ternatively spliced sites. 
SNPs and Non-Coding RNAs 
  A further layer of complexity in the interplay between 
GVs and epigenetic marks is represented by micro RNAs 
(miRNAs). miRNAs are short, endogenous 18-25-nucleotide 
long RNAs that were originally identified as translational 
repressors mediating the degradation of specific target 
mRNAs [70]. miRNAs are of potential interest in the context 
of this review, as they have been recognized as modifiers of 
DNA methylation at specific target sequences in plants and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic effects of GV on epigenetic marks. A, allele (a and b, respectively)-specific regulation of local DNA methylation states 
and examples of possible biological effects. Vertical lines mark GV position. Open and closed circles represent unmethylated and methylated 
residues, respectively. The b allele is hypothetically represented as the one associated with DNA hypermethylation spreading to adjacent 
sequences (arrows). B, normal expression patterns of two adjacent genes (left) are altered if a deletion in polyadenylation signal sequence of 
the upstream gene causes transcript extension to and silencing of a downstream gene (right). Closed circles on the right indicate hypermethy-
lation of the overrun promoter of the downstream gene. C, long-range transcriptional impact of GV-associated epigenetic marks. The b allele 
is associated with enhancer-like histone marks (star) positioned in a chromatin loop extending to a gene promoter (white rectangle). D, non-
coding SNP-containing transcripts (curved lines) regulate expression and epigenetic marks of different target genes (white boxes) depending 
on genotype. See [2,58,59,63,64,72] and text for details. 364    Current Genomics, 2010, Vol. 11, No. 5  Zaina et al. 
therefore possibly in humans as well [71]. Two reports indi-
cate that SNPs can impact on miRNA function. The first 
shows that a SNP is in principle sufficient to alter maturation 
of miRNA precursors into shorter active miRNAs [72]. The 
mechanisms underlying these phenomena are not clear, as 
SNPs have been detected in miRNA residues involved in 
target recognition rather than precursor processing. Similar 
conclusions were drawn by subsequent reports that have 
been recently reviewed in detail [73]. The second, analysed 
the impact of intergenic SNPs on miRNA profiles [2]. As we 
mentioned above, the same study concluded that intergenic 
SNPs are a significant proportion of human disease-
associated SNPs. This information was coupled with histone 
signature data suggesting that many of these intergenic SNPs 
may be actively transcribed. The authors went on showing 
that a number of intergenic SNPs associated with inflamma-
tory and autoimmune diseases are included in 100-200 nu-
cleotide-long transcripts. These intergenic transcripts (re-
ferred to in the study as transRNAs) exert dramatic effects 
on the expression of large numbers of miRNAs and mRNAs. 
Furthermore, expression of short 52 nn-long sense and an-
tisense SNP-including intergenic transcripts resulted in 
markedly different, allele-specific miRNA and mRNA signa-
tures involved in a number of disease-related pathways (Fig. 
1D) [2]. Interestingly, specific SNP-containing intergenic 
transcript alleles regulated a number of chromatin modifier 
genes, thus directly linking SNPs and epigenetic regulation.  
CONCLUSIONS 
  Recent literature offers abundant proof of principle that 
the interplay between GV and epigenetic marks may be a 
widespread mechanism of transcriptional regulation. From 
the point of view of genetic association studies, epigenetics 
may explain the relevance of non-coding and intergenic 
GVs. Additionally, epigenetics may shed light on cases of 
biologically relevant GVs that show contrasting results be-
tween different countries and ethnic groups. For example, 
the interplay between rs6983267 genotype and c-MYC acti-
vation discussed above is controversial, as a number of stud-
ies failed to detect any significant association (discussed in 
[74]). In particular, the latter study identified a strong asso-
ciation between a splicing variant of the rs6983267-
interacting TCF7L2 transcription factor, but not rs6983267 
genotype, and c-MYC expression [74]. This inconsistency 
may have multiple explanations, but it may be revelatory of 
the inherent difficulties in relating epigenetic modifications, 
GV genotype and phenotype. A scenario can be envisioned, 
in which diet and environment affect epigenetic marks that 
control TCF7L2 alternative splicing and rs6983267 chroma-
tin structure. This view is consistent with the idea that se-
quences undergoing epigenetic mark transitions, such as 
some of CpG SNP-containing ones, are expected to be rela-
tively more prone to resetting [51]. It is possible that diet and 
environment induce epigenetic marks with opposite effects 
on  c-MYC transcription, for example locking rs6983267 
chromatin in a non-enhancer architecture, but favouring 
TCF7L2 splicing variants that activate c-MYC transcription. 
If that were the case, particular population-specific dietary 
and environmental conditions would mask the association of 
c-MYC expression with rs6983267 genotype to the advan-
tage of its association with TCF7L2 transcript variants. A 
simplified view of this process is proposed in Fig. (2). From 
the point of view of type 2 diabetes, whether intronic 
TCF7L2 SNPs as the ones discussed in the first section affect 
local DNA methylation states and consequently splicing in a 
diet- and environment-dependent fashion, it is to our knowl-
edge a yet unanswered question.  
 
 
 
 
 
 
 
 
Fig. (2). Simplified view of how dietary, environmental and possi-
bly other exogenous factors can interfere with the establishment of 
allele-specific DNA methylation states and complicate comparisons 
between genetic association studies conducted in different popula-
tions. In population 1, those exogenous factors are weak or neutral 
and the b allele associates with local DNA hypermethylation com-
pared to allele a (symbols are as in legend of Fig. 1). In population 
2, exogenous factors (grey ovals) distinct in dose or type from the 
ones affecting population 1 override allele b-specific effects and 
lock both a and b alleles in a hypermethylated state. If b allele-
associated and exogenous factor-induced epigenetic marks are 
comparable, genetic associations will be masked in population 2. 
For simplicity, DNA hypermethylation is represented as the effect 
of diet-related or environmental factors, but DNA hypomethylation 
is an equally likely outcome. 
  The evidence discussed in this review suggests that the 
rich tapestry of genotype-phenotype interactions can in some 
cases be interpreted only by interdisciplinary genetic associa-
tion studies that take into account biological features such as 
transcript structure and level, DNA methylation states, his-
tone marks and high-order chromatin structure, and stratify 
study populations accordingly. If this assumption holds true, 
any viable claim to implement personalized medicine will 
have to deal with those additional components as a comple-
ment to individual patient genome sequence information. 
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